Crisugabalin, a ligand for the αδ subunit of voltage-gated calcium channels, exhibits no obvious abuse potential in rodents
Pharmacology Biochemistry and Behavior · 2025
DOI: 10.1016/j.pbb.2025.174015 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacology Biochemistry and Behavior, 2025. Verfasst von Xiaoli Gou und 11 weiteren Autor:innen. Beteiligte Einrichtung: Haisco Pharmaceutical Group Co., Ltd., 136 Baili Rd, Wenjiang District, Chengdu, Sichuan 611130, China. Hauptthemen laut MEDLINE: Calcium Channels, Bridged Bicyclo Compounds, Substance-Related Disorders. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 46 Literaturangaben. Gefördert von: Key Technologies Research and Development Program.
Abstract (Originalsprache)
Crisugabalin, a novel third-generation ligand targeting the α2δ subunit of voltage-gated calcium channels, has been approved in China for the treatment of pain associated with diabetic peripheral neuropathy and postherpetic neuralgia. Existing research suggests that ligands for the α2δ subunit of voltage-gated calcium channels may carry a risk of abuse. To evaluate the abuse potential of crisugabalin, five well-recognized animal models were utilized in these preclinical studies. Firstly, an intravenous self-administration paradigm was implemented in rats that were self-administering propofol to assess the reinforcing effects of crisugabalin. Secondly, a rat drug discrimination study was employed to determine the pharmacological similarity between crisugabalin and the training drug midazolam. Then, a conditioned place preference (CPP) paradigm in rats was utilized to evaluate the rewarding properties of crisugabalin. After that, a spontaneous withdrawal study was conducted in rats chronically treated with crisugabalin to examine the liability of developing physical dependence. Finally, a mouse pentylenetetrazol-induced convulsion model was used following chronic exposure to crisugabalin to assess its potential for physical dependence. The results indicated that crisugabalin showed no positive reinforcing effects and did not display midazolam-like discriminative stimulus effects. Moreover, crisugabalin did not induce significant CPP in rats and there was no risk of physical dependence in the pentylenetetrazol-induced convulsion model. In the rat spontaneous withdrawal study, crisugabalin demonstrated a very low level of physical dependence. These findings suggest that crisugabalin has minimal to no potential for abuse, thereby establishing itself as a safer option relative to pregabalin and mirogabalin.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Haisco Pharmaceutical Group Co., Ltd., 136 Baili Rd, Wenjiang District, Chengdu, Sichuan 611130, China.
- Hangzhou Chuanhe Lingjing Technology Co., Ltd., No. 9 Jiusheng Road, Shangcheng District, Hangzhou 310013, China.
- NMPA Key Laboratory of Quality Monitoring of Anaesthetic and Psychotropic Substances, Chongqing Institute for Food and Drug Control, No.1 Chunlan Second Road, Yubei District, Chongqing 401121, China.
- Saifu Laboratories Co., Ltd., No. 2, Kechuang 6th Street, Beijing Economic and Technological Development Zone, Beijing 100176, China; Saifu Laboratories Gu'an Co., Ltd. (former name SAFE Medical Technology Co., Ltd.), E…
- Haisco Pharmaceutical Group Co., Ltd., 136 Baili Rd, Wenjiang District, Chengdu, Sichuan 611130, China. Electronic address: wangju@haisco.com.
- NMPA Key Laboratory of Quality Monitoring of Anaesthetic and Psychotropic Substances, Chongqing Institute for Food and Drug Control, No.1 Chunlan Second Road, Yubei District, Chongqing 401121, China. Electronic address:…
Förderung
- Key Technologies Research and Development Program
Zitieren
APA
Gou, X., Liu, Y., Ye, Q., He, L., Chen, Y., Dong, Y., Meng, Q., Shi, Z., Li, Y., Lu, Y., Wang, J., & Zeng, L. (2025). Crisugabalin, a ligand for the αδ subunit of voltage-gated calcium channels, exhibits no obvious abuse potential in rodents. Pharmacology Biochemistry and Behavior. https://doi.org/10.1016/j.pbb.2025.174015
Vancouver
Gou X, Liu Y, Ye Q, He L, Chen Y, Dong Y, et al. Crisugabalin, a ligand for the αδ subunit of voltage-gated calcium channels, exhibits no obvious abuse potential in rodents. Pharmacology Biochemistry and Behavior. 2025. doi:10.1016/j.pbb.2025.174015
BibTeX
@article{Gou2025,
author = {Gou, Xiaoli and Liu, Yijiang and Ye, Qidi and He, Lingzhi and Chen, Ying and Dong, Yansheng and Meng, Qingyuan and Shi, Zongjun and Li, Yao and Lu, Yao and Wang, Ju and Zeng, Linggao},
title = {Crisugabalin, a ligand for the αδ subunit of voltage-gated calcium channels, exhibits no obvious abuse potential in rodents},
journal = {Pharmacology Biochemistry and Behavior},
year = {2025},
doi = {10.1016/j.pbb.2025.174015}
}
EUVIMED